Bromide

Bromide

SCHEMBL4827485

[Br-].c1ccc(OCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 9/20 0.69
KCNA3 P22001 1/20 0.59
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
HIF1A Q16665 1/20 0.50
PSMB5 P28074 2/20 0.48
PSMB1 P20618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1171472 1.00 CHRNA7 (0.69) CHRNA7KCNA3HDAC3HDAC4HDAC1
Bromide SCHEMBL1172199 0.98 CHRNA7 (0.69) CHRNA7KCNA3HDAC3HDAC4HDAC1
Bromide SCHEMBL4827422 0.92 CHRNA7 (0.68) CHRNA7KCNA3HDAC3HDAC4HDAC1
Bromide SCHEMBL4827493 0.86 HIF1A (0.56) CHRNA7KCNA3HDAC3HDAC4HDAC1
Bromide SCHEMBL3092089 0.86 CHRNA7 (0.64) CHRNA7KCNA3PSMB5PSMB1
Bromide SCHEMBL10362108 0.85 CHRNA7 (0.53) CHRNA7KCNA3
Bromide SCHEMBL3391859 0.84 HIF1A (0.70) CHRNA7HIF1A
Bromide SCHEMBL4184421 0.84 HIF1A (0.70) CHRNA7HIF1A
Bromide SCHEMBL2450121 0.84 HIF1A (0.70) CHRNA7HIF1A
Bromide SCHEMBL52420 0.84 HIF1A (0.70) CHRNA7HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746113-B2 Labelled cannabinergic ligands and related analogs MAKRIYANNIS ALEXANDROS (US) 2023-09-05 US disclosed
US-20210300937-A1 Novel Labelled Cannabinergic Ligands and Related Analogs MAKRIYANNIS ALEXANDROS (US) 2021-09-30 US disclosed
US-9517989-B2 2-cycloalkyl resorcinol cannabinergic ligands NORTHEASTERN UNIVERSITY (US) 2016-12-13 US disclosed
US-20150274623-A1 2-CYCLOALKYL RESORCINOL CANNABINERGIC LIGANDS Northeastern Uiversity (US) 2015-10-01 US disclosed
WO-2014062965-A1 2-CYCLOALKYL RESORCINOL CANNABINERGIC LIGANDS NORTHEASTERN UNIVERSITY (US) 2014-04-24 WO disclosed
US-7446229-B2 Bicyclic cannabinoids UNIVERSITY OF CONNECTICUT (US) 2008-11-04 US disclosed
US-20070135388-A1 Novel Bicyclic Cannabinoids UNIVERSITY OF CONNECTICUT 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746113-B2 Labelled cannabinergic ligands and related analogs CNR1, CNR2, CHRND CHRNA7 33/4885KCNA3 779/4885HDAC3 2338/4885
US-20150274623-A1 2-CYCLOALKYL RESORCINOL CANNABINERGIC LIGANDS CNR2, CNR1, OPRL1 CHRNA7 117/4885KCNA3 1312/4885HDAC3 2853/4885
US-20210300937-A1 Novel Labelled Cannabinergic Ligands and Related Analogs CNR1, CNR2, CHRND CHRNA7 28/4885KCNA3 774/4885HDAC3 2454/4885
US-20070135388-A1 Novel Bicyclic Cannabinoids CNR2, CNR1, GPR18 CHRNA7 161/4885KCNA3 978/4885HDAC3 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.